Advertisement

Picture Demy-Colton BioFuture 2024 NYC 3 Biotech Breakthroughs 650x100px
Document › Details

CRISPR Therapeutics AG. (2/21/23). "Press Release: CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results". Zug & Boston, MA.

Organisations Organisation CRISPR Therapeutics AG (Nasdaq: CRSP)
  Group CRISPR Therapeutics (Group)
  Organisation 2 Vertex Pharmaceuticals Inc. (Nasdaq: VRTX)
  Group Vertex Pharmaceuticals (Group)
Products Product exagamglogene autotemcel (exa-cel) (formerly CTX001)
  Product 2 CTX130 allogeneic CAR T-cell therapy
Persons Person Harding, Alex (CRISPR Therapeutics 202301– Head BusDev before Remix Theraepeutics + Atlas Venture)
  Person 2 Kulkarni, Samarth (Sam) (CRISPR Therapeutics 201712– promoted CEO before CBO)
     


   
Record changed: 2024-01-20

Advertisement

Picture Demy-Colton BioFuture 2024 NYC 3 Healthcare Revolution 650x200px

More documents for CRISPR Therapeutics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Demy-Colton BioFuture 2024 NYC Reimagine Healthcare 650x300px




» top